A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant T

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT07239466 by Tao Zhang, with a registry enrolment figure of 25 participants, started 2026-01-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Short-course radiotherapy; Capecitabine; Oxaliplatin; TME surgery; β-hydroxybutyrate. Conditions listed: Rectal Cancer; Radiotherapy; Immunotherapy; Chemotherapy. Primary outcome: complete response (CR) rate. Colorectal eligibility wording from the registry: "Histologically confirmed Locally Advanced rectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.